LivaNova Launches Epilepsy App, Scores €82M Tax Win, Needham Lifts PT to $93
LIVN sits 87% above its 52-week low of $41.87 on elevated volume (2.4× avg).
Summary
LivaNova launched a limited release of its cloud clinician portal and epilepsy app, with a wider rollout and an implantable pulse generator planned for 2027. Separately, the company secured an €81.8M tax benefit from an Italian ruling on SNIA environmental liability, though remediation provisions remain ongoing. Needham raised its price target to $93 from $81, maintaining a Buy rating. These developments follow strong Q2 results reported yesterday, where revenue beat estimates and guidance was raised. The tax benefit adds a material non-recurring boost to net income, while the app launch advances the neuromodulation pipeline. The OSA MRI-compatible PMA submission is expected H2 2026–H1 2027.
At the time of this announcement, LIVN was trading at $78.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $41.87 to $85.76. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.